Harmony Biosciences (HRMY) Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last twelve months. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HRMY shares.
View HRMY analyst ratings or view top-rated stocks.

10 Wall Street analysts have issued 1-year target prices for Harmony Biosciences' stock. Their HRMY share price forecasts range from $43.00 to $75.00. On average, they anticipate the company's share price to reach $60.78 in the next year. This suggests a possible upside of 76.9% from the stock's current price.
View analysts price targets for HRMY or view top-rated stocks among Wall Street analysts.

Harmony Biosciences' stock was trading at $55.10 on January 1st, 2023. Since then, HRMY shares have decreased by 37.6% and is now trading at $34.36.
View the best growth stocks for 2023 here.

Harmony Biosciences saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 7,350,000 shares, a decline of 5.0% from the August 31st total of 7,740,000 shares. Based on an average daily volume of 532,100 shares, the days-to-cover ratio is currently 13.8 days. Approximately 21.6% of the shares of the company are short sold.
View Harmony Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our HRMY earnings forecast.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced its quarterly earnings results on Tuesday, August, 1st. The company reported $0.56 earnings per share for the quarter, missing the consensus estimate of $0.62 by $0.06. The company earned $134.22 million during the quarter, compared to analysts' expectations of $139.79 million. Harmony Biosciences had a net margin of 40.16% and a trailing twelve-month return on equity of 42.49%.

ETFs with the largest weight of Harmony Biosciences (NASDAQ:HRMY) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Products ETF (BBP), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco S&P SmallCap Health Care ETF (PSCH) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).iShares U.S. Pharmaceuticals ETF (IHE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN).

(HRMY) raised $101 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 4,700,000 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO.

Harmony Biosciences trades on the NASDAQ under the ticker symbol "HRMY."

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HRMY stock can currently be purchased for approximately $34.36.

Harmony Biosciences (NASDAQ:HRMY) has a market capitalization of $2.06 billion and generates $437.86 million in revenue each year. The company earns $181.47 million in net income (profit) each year or $3.27 on an earnings per share basis.

The company employs 200 workers across the globe.

Harmony Biosciences' mailing address is 630 W GERMANTOWN PIKE SUITE 215, PLYMOUTH MEETING PA, 19462. The official website for the company is www.harmonybiosciences.com. The company can be reached via phone at 484-539-9800 or via email at lcaperelli@harmonybiosciences.com.